137 related articles for article (PubMed ID: 16052341)
1. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.
Jermann M; Stahel RA; Salzberg M; Cerny T; Joerger M; Gillessen S; Morant R; Egli F; Rhyner K; Bauer JA; Pless M
Cancer Chemother Pharmacol; 2006 Apr; 57(4):533-9. PubMed ID: 16052341
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.
Dawson NA; Guo C; Zak R; Dorsey B; Smoot J; Wong J; Hussain A
Clin Cancer Res; 2004 Dec; 10(23):7812-9. PubMed ID: 15585612
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.
Drucker B; Bacik J; Ginsberg M; Marion S; Russo P; Mazumdar M; Motzer R
Invest New Drugs; 2003 Aug; 21(3):341-5. PubMed ID: 14578682
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
Goncalves A; Fabbro M; Lhommé C; Gladieff L; Extra JM; Floquet A; Chaigneau L; Carrasco AT; Viens P
Gynecol Oncol; 2008 Jan; 108(1):42-6. PubMed ID: 17980406
[TBL] [Abstract][Full Text] [Related]
6. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
Santoro A; Cavina R; Latteri F; Zucali PA; Ginanni V; Campagnoli E; Ferrari B; Morenghi E; Pedicini V; Roncalli M; Alloisio M; Ravasi G; Soto Parra HJ
Ann Oncol; 2004 Jan; 15(1):33-7. PubMed ID: 14679116
[TBL] [Abstract][Full Text] [Related]
7. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial.
Amato RJ; Jac J; Hernandez-McClain J
Anticancer Drugs; 2008 Jun; 19(5):527-33. PubMed ID: 18418219
[TBL] [Abstract][Full Text] [Related]
9. Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma.
Gemmill RM; Zhou M; Costa L; Korch C; Bukowski RM; Drabkin HA
Br J Cancer; 2005 Jun; 92(12):2266-77. PubMed ID: 15956968
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
11. Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program.
Razis E; Skarlos D; Briasoulis E; Dimopoulos M; Fountzilas G; Lambropoulos S; Rigatos S; Kopterides P; Efstathiou H; Tzamakou E; Bakoyannis C; Pectasides D; Makatsoris T; Varthalitis G; Papadopoulos S; Kosmidis P
Anticancer Drugs; 2005 Feb; 16(2):191-8. PubMed ID: 15655417
[TBL] [Abstract][Full Text] [Related]
12. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
Cohen MH; Williams GA; Sridhara R; Chen G; McGuinn WD; Morse D; Abraham S; Rahman A; Liang C; Lostritto R; Baird A; Pazdur R
Clin Cancer Res; 2004 Feb; 10(4):1212-8. PubMed ID: 14977817
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma.
Shek D; Longmate J; Quinn DI; Margolin KA; Twardowski P; Gandara DR; Frankel P; Pan CX; Lara PN
Int J Clin Oncol; 2011 Oct; 16(5):494-9. PubMed ID: 21431345
[TBL] [Abstract][Full Text] [Related]
14. Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study.
Xu Y; Zheng Y; Sun X; Yu X; Gu J; Wu W; Zhang G; Hu J; Sun W; Mao W
Oncotarget; 2015 Nov; 6(35):38429-39. PubMed ID: 26392415
[TBL] [Abstract][Full Text] [Related]
15. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
17. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib (Iressa) in metastatic patients with non-small cell lung cancer: preliminary experience in a Brazilian center.
del Giglio A; Ito C
Sao Paulo Med J; 2004 May; 122(3):128-30. PubMed ID: 15448812
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Mok TS; Wu YL; Thongprasert S; Yang CH; Chu DT; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; Yang JJ; Chewaskulyong B; Jiang H; Duffield EL; Watkins CL; Armour AA; Fukuoka M
N Engl J Med; 2009 Sep; 361(10):947-57. PubMed ID: 19692680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
